Johnson & Johnson's Steady Performance and Innovation Outlook

# Johnson & Johnson Stock Update: Q2 Earnings Preview & Analyst Outlook Johnson & Johnson (JNJ) closed recent trading at $157.69, with after-hours movement suggesting continued momentum as investors prepare for the company's upcoming Q2 earnings report. With trading volume lighter than usual at just 77% of daily averages, market participants appear to be in a holding pattern ahead of key financial disclosures. ## Q2 Earnings Expectations The pharmaceutical giant is scheduled to release its Q2 2024 results on July 16th, with analyst projections pointing to: - Earnings of $2.68 per share (lower than previous year) - Revenue forecast of approximately $22.86 billion - Ongoing innovation highlighted by recent FDA submission for CAPLYTA targeting schizophrenia relapse prevention ## Analyst Sentiment Remains Positive Wall Street maintains a generally favorable outlook on JNJ: - Morgan Stanley: Price target raised to $171 with "equal weight" rating - Goldman Sachs: "Conviction buy" with $177 target, citing strength in Tremfya and Carvykti treatments - Consensus target of approximately $170 represents 7-8% upside potential - Most analysts rate the stock between "moderate buy" and "outperform" Despite ongoing talc litigation concerns, JNJ has outperformed pharmaceutical peers with an 8% gain year-to-date. The company's strong position in innovative medicine and medtech, combined with an attractive dividend yield exceeding 3%, continues to provide investor confidence in an otherwise cautious market environment. #Investing #Pharmaceuticals #StockAnalysis #JNJ #EarningsPreview For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.